First 10 runs free
    Intelligence Feed event · Equity · 2026-10-26

    J&J reports 77% response rate for subcutaneous amivantamab regimen in head and neck cancer

    Question

    J&J reports 77% response rate for subcutaneous amivantamab regimen in head and neck cancer

    Direct answer

    Johnson & Johnson announced results from its Phase 1b/2 OrigAMI-4 study testing subcutaneous amivantamab (Rybrevant) in combination with pembrolizumab and carboplatin. The tripartite regimen achieved a 77% overall response rate in first-line treatment for advanced recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The findings demonstrate high response metrics in non-HPV-associated HNSCC, offering clinical backing for J&J's broader oncology franchise lifecycle management.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-26
    Published
    2026-10-26
    Revision
    1 · 2026-10-28

    Cite as: Market Ontology, “J&J reports 77% response rate for subcutaneous amivantamab regimen in head and neck cancer”, revision 1, evidence through 2026-10-26. https://marketontology.com/market-events/2026-10-26/j-j-reports-77-response-rate-for-subcutaneous-amivantamab-regimen-in-head-and-ne-afc0ea

    EQUITY
    J&J reports 77% response rate for subcutaneous amivantamab regimen in head and neck cancer
    Johnson & Johnson announced results from its Phase 1b/2 OrigAMI-4 study testing subcutaneous amivantamab (Rybrevant) in combination with pembrolizumab and carboplatin. The tripartite regimen achieved a 77% overall response rate in first-line treatment for advanced recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The findings demonstrate high response metrics in non-HPV-associated HNSCC, offering clinical backing for J&J's broader oncology franchise lifecycle management.
    JNJMRK
    Impact
    72
    OCT 26
    SIG
    88%
    JNJMRK
    J&J reports 77% response rate for subcutaneous amivantamab regimen in head and neck cancer
    Johnson & Johnson announced results from its Phase 1b/2 OrigAMI-4 study testing subcutaneous amivantamab (Rybrevant) in combination with pembrolizumab and carboplatin. The tripartite regimen achieved a 77% overall response rate in first-line treatment for advanced recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The findings demonstrate high response metrics in non-HPV-associated HNSCC, offering clinical backing for J&J's broader oncology franchise lifecycle management.
    → A 77% confirmed response rate supports J&J's Rybrevant label expansion into first-line solid tumor regimens, expanding commercial drug demand.
    Impact
    Johnson & Johnson announced results from its Phase 1b/2 OrigAMI-4 study testing subcutaneous amivantamab (Rybrevant) in combination with pembrolizumab and carboplatin. The tripartite regimen achieved a 77% overall response rate in first-line treatment for advanced recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The findings demonstrate high response metrics in non-HPV-associated HNSCC, offering clinical backing for J&J's broader oncology franchise lifecycle management.
    Affected
    JNJMRK
    Transmission
    A 77% confirmed response rate supports J&J's Rybrevant label expansion into first-line solid tumor regimens, expanding commercial drug demand.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    JNJoncology product commercial addressable market expansion via Rybrevant trialUp1-4wJohnson & Johnson announced Phase 1b/2 OrigAMI-4 study results showing subcutaneous amivantamab regimen achieved 77% overall response rate.
    MRKcombination therapy demand pull-through for pembrolizumabUp1-4wSubcutaneous amivantamab was combined with pembrolizumab in the OrigAMI-4 study.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    JNJUp266.30 2026-10-26PendingPendingPending
    MRKUpagreed140.61 2026-10-26+0.86%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    Find trades for this development

    Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.

    First 10 runs free

    First 10 runs free

    See today's live cards

    Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open live cards